Jales

Researchers are evaluating the use of adjuvant chemotherapy in patients with locally advanced cervical cancer who test positive for cell-free human papillomavirus deoxyribonucleic acid (cfHPV-DNA) in their plasma after standard treatment. This Phase 3, randomized, multicenter clinical trial aims to determine if patients with persistent cfHPV-DNA expression after chemoradiotherapy can benefit from additional chemotherapy. The study includes patients with cervical cancer stages IB3 to IVA who have completed standard concomitant chemoradiotherapy.

Researchers are conducting a Phase III randomized clinical trial to evaluate the order of giving anthracyclines and taxanes as neoadjuvant chemotherapy for locally advanced HER2-negative breast cancer. The study includes 494 female patients with invasive breast carcinoma, focusing on whether starting treatment with anthracyclines or taxanes affects outcomes. Patients with triple-negative breast cancer may also receive carboplatin as part of their treatment. Participants will be randomized into two groups receiving the same chemotherapy drugs but in different sequences. One group will start with doxorubicin and cyclophosphamide given intravenously every 21 days for 3 cycles, while the other will start with either docetaxel given every 21 days for 4 cycles or weekly paclitaxel for 12 weeks. Other treatments such as surgery, radiotherapy, and hormone therapy will be given according to standard care and are not part of this study. During the study, participants will be closely monitored for invasive disease-free survival over an average of 8 years. Before starting treatment, patients will undergo assessments including cardiac function tests and evaluations of overall health and organ function. Researchers will collect data on treatment effects, safety, and survival outcomes to better understand the best sequence of chemotherapy drugs for this breast cancer type.